BIB

Why This Biotech ETF Keeps Surging | ETF Trends

Why This Biotech ETF Keeps Surging | ETF TrendsHere is a new biotech ETF stock that is worth buying, BBP. They seem to be doing well at picking winners. I plan to buy BBP soon even though I already own BIB and XBI. I believe good biotech stocks will outperform the general market easily.

View post – 

Why This Biotech ETF Keeps Surging […]

Is Biotech Finally In A Bubble? | Seeking Alpha

Is Biotech Finally In A Bubble? | Seeking AlphaDoctoRx has written an outstanding article on the biotech sector. I agree 100% with the doctor that biotech stocks are worth a good portion of your portfolio. I own XBI, the small cap biotech ETF, and BIB, the 2x leveraged ETF for large cap biotech stocks. These two stocks have far outperformed […]

Nasdaq Biotech vs. S&P Biotech

Biotech stocks have been in a strong Upward trend for years. Both ETFs Nasdaq (IBB) and S&P (XBI) have been top performers. Recently the S&P (XBI) has rallied on to all time highs. The Nasdaq (IBB) has failed to take out all time highs. The Proshares Nasdaq Biotech ETF (2X) (BIB) is an excellent instrument. Now Direxionshares has recently introduced […]

Getting it Right (and Wrong) With Leveraged Biotech ETFs

In what looks like a sequel to March 2014, high-flying biotechnology stocks and exchange traded funds are retreating amid talk of frothy valuations and a biotech bubble.At least temporarily, Friday March 20 marked the top for several of the largest biotech ETFs. That is when big-name ETFs, such as the iShares Nasdaq Biotechnology ETF (IBB) , the largest biotech ETF, […]

ProShares Launches Listed Private Equity ETF

[Business Wire] – ProShares, a premier provider of alternative ETFs, today announced the launch of ProShares Global Listed Private Equity ETF . PEX is the first globally diversified ETF f moreView todays social media effects on BIBView the latest stocks trending across Twitter. Click to view dashboardSee who ProShares is hiring next, click here to view […]

ProShares Lowers Net Expense Ratio for CSM, a Morningstar Rated 5-Star ETF

[Business Wire] – ProShares, a leading provider of alternative ETFs, announced that effective today, it is lowering the net expense ratio for CSM, a Morningstar rated 5-star ETF, from 95 to 45 basis points. moreView todays social media effects on BIBView the latest stocks trending across Twitter. Click to view dashboardSee who ProShares is hiring next, click here to view […]

ProShares Launches First True Merger Arbitrage ETF

[Business Wire] – ProShares, a premier provider of alternative exchange traded funds , today announced the launch of the ProShares Merger ETF , the first ETF based on a true merger arbitrage strategy. moreView todays social media effects on BIBView the latest stocks trending across Twitter. Click to view dashboardSee who ProShares is hiring next, click here to view […]